Please login to the form below
siltuximab
This page shows the latest siltuximab news and features for those working in and with pharma, biotech and healthcare.
EC approves Janssen rare blood disorder drug
Sylvant (siltuximab) offers a more promising alternative, however, and has demonstrated in clinical trials it can reduce the size of tumours and stabilise disease symptoms, such as fever. ... Not every MCD patient will be eligible for treatment with
Latest news
-
FDA approves Janssen drug for rare Castleman’s disease
Sylvant (siltuximab), marketed by Johnson &Johnson subsidiary Janssen Biotech, is the first drug backed by the FDA to treat multicentric Castleman's disease, which the agency describes as a rare disorder
-
J&J files rare blood disorder drug siltuximab in US and EU
Johnson &Johnson (J&J) has filed for approval of its investigational drug siltuximab in both the EU and US as a treatment for a rare blood disorder. ... The submissions are based primarily on data from the randomised MCD2001 study, which compared
-
J&J positive about pipeline
Also on the list are fulranumab for osteoarthritis pain; siltuximab for castleman's disease, a rare disorder that is similar to lymphoma; TMC-207 for MDR tuberculosis; TMC 435 for hepatitis
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Featured jobs
-
Account Director
-
£48, 000 - £60, 000
-
Associate Medical Director
-
Highly Competitive
- Senior Account Executive, London, Medical Communications
-
Excellent package
-
Medical Writers
-
Competitive Salary and Benefits
- Scientific Director / Editorial Team Leader
-
Great salary and benefits
- Director, Market Access / HEOR - North-West
-
Negotiable
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
-
Associate Director
-
£75, 000-90, 000
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
- Account Manager, Healthcare Public Affairs
-
£32, 000 – £40, 000 benefits
- Senior Systematic Review Analyst - Oxford
-
Negotiable
- Events Manager – Med Comms – Surrey
-
Salary TBC
- Programme Director, Healthcare PR, Highly competitive package
-
Highly Competitive package
-
Senior Account Manager
-
Negotiable
-
New Business Director - PR
-
Competitive Salary and benefits
Subscribe to our email news alerts
- Stem Cell Therapies Market Volume Forecast and Value Chain Analysis 2015 - 2025
- Small Animal Imaging (In Vivo) Market to Witness Robust Expansion throughout the Forecast 2016- 2026
- Advance Renal Cell Carcinoma Therapeutics Market Prophesied to Grow at a Faster Pace by 2026
- Nasal Implant Market Volume Analysis, Segments, Value Share and Key Trends 2016-2026
- Equine Veterinary Therapeutics Market Growth, Trends, Absolute Opportunity and Value Chain 2016-2026
- Limb Salvage Systems Market Value Share, Supply Demand, share and Value Chain 2016-2026
PMHub
OPEN Access Consulting
OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...
Latest intelligence
- Innovation in merger control and the impact on the pharmaceutical sector
- Is focusing on pipeline products enough to assess regulatory risks?...
- Nudge-nudge, think-think
- Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...
- Quality in Care Diabetes 2018: the best in innovative diabetes care
- Awards highlight new evidence-based approaches to improving care...
Quick links
Infographics
